FIELD: chemistry.
SUBSTANCE: invention relates to the field of special mattresses with two or more independently filled chambers and with contents from chemical foam materials. Military field bed (MFB) for use in military field, combat and/or in unfavourable weather and climatic conditions, contains a two-layer sealed shell made of non-damp and/or waterproof and/or water-repellent fabric material. Shell is connected into a single whole by means of seams and is simultaneously divided by means of the same seams into tight hollow chambers. All chambers are connected by seams into a single shell, the seams are created by stitching the shell with thread, or by gluing the shell in places between chambers or by thermoforming layers of the shell. Chambers are isolated from each other or are connected to each other and are intended for their filling with chemical filler (CF) of initial liquid and/or gaseous state with subsequent process of its polymerisation, secondary expansion and hardening of CF with the possibility of imparting rigidity and required thickness to the shell chambers, low thermal conductivity, high heat resistance and fire resistance, and required buoyancy. Shell is equipped with one-way valves for pumping CF under pressure into chambers, uniform distribution of CF in chambers and subsequent polymerization of CF with corresponding increase of proper initial volume with required density, gluing of CF from inside of shell fabric, reinforcing mesh, slings, due to adhesion of CF with all elements of the lounger, fixation of the obtained cellular chamber structure of the shell. Outer side of the casing chambers after polymerization and hardening of the CF gains a sloping rounded shape. Foamed polyurethane foam (FPF) is used as the CF.
EFFECT: increased operational efficiency of the device in extreme, difficult conditions of its use, and expansion of functionality.
8 cl, 8 dwg
Title | Year | Author | Number |
---|---|---|---|
PHARMACEUTICAL COMPOSITION FOR TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ALPRAZOLAM | 2018 |
|
RU2694232C1 |
METHOD OF TREATMENT OF INFECTED WOUNDS | 2016 |
|
RU2648026C1 |
MEDICINAL PRODUCT WITH ANTICOAGULANT (INHIBITOR OF FACTOR IIA), ANTITHROMBOTIC, ANTI-INFLAMMATORY ACTIVITIES AND CONTAINING 5,7-DI(THIOPHEN-2-IL)-4,5-DIHYDRO-[1,2,4]TRIAZOLO[1,5-a ]PYRIMIDINE | 2022 |
|
RU2798587C1 |
METHOD OF USING HYDROXYCHLOROQUINE AND DERIVATIVES THEREOF FOR DELIVERING CHEMOTHERAPEUTIC DRUG TO CANCER FOCUS (EMBODIMENTS) | 2023 |
|
RU2834400C2 |
MULTI-COMPONENT MELATONINE-CONTAINING PREPARATION FOR ORAL TISSUE REGENERATION AND METHOD FOR PRODUCING IT | 2013 |
|
RU2552330C1 |
DRUG WITH IMMUNOMODULATORY EFFECT | 2016 |
|
RU2629331C1 |
ANTI-PD-1 ANTIBODIES, METHOD FOR THEIR PRODUCTION, AND METHOD OF APPLICATION | 2016 |
|
RU2656181C1 |
MONOCLONAL PD-L1 ANTIBODY | 2017 |
|
RU2665790C1 |
Authors
Dates
2024-05-30—Published
2023-03-21—Filed